Finance

Beta
Lists
FPH:NZE
Fisher & Paykel Healthcare Corporatn Ltd
NZ$37.18
+0.92%
(+0.34) 1D
Jun 5, 5:00:18 PM GMT+12  ·   NZD
All symbols
SymbolPriceChange% Change
Generating top insights for FPH...
Open
NZ$36.70
High
NZ$37.20
Low
NZ$36.70
Mkt. cap
21.64B
Avg. vol.
598.37K
Volume
394.19K
Dividend
1.40%
Quarterly dividend
NZ$0.13
Ex-dividend date
Jun 22, 2026
P/E ratio
46.90
52-wk high
NZ$41.40
52-wk low
NZ$32.16
EPS
NZ$0.79
Shares outstanding
587.29M
No. of employees
7K
Open
NZ$36.70
High
NZ$37.20
Low
NZ$36.70
Mkt. cap
21.64B
Avg. vol.
598.37K
Volume
394.19K
Dividend
1.40%
Quarterly dividend
NZ$0.13
Ex-dividend date
Jun 22, 2026
P/E ratio
46.90
52-wk high
NZ$41.40
52-wk low
NZ$32.16
EPS
NZ$0.79
Shares outstanding
587.29M
No. of employees
7K
Analyst outlook
Analyst Ratings
Based on 9 analysts giving stock ratings to FPH in the past 3 months
Buy
Buy
5
Hold
4
Sell
0
12 month forecast
Based on 9 Wall Street analysts offering 12 month price targets for FPH in the last 3 months.
Highest
Current A$37.18
A$39.50 (+6.24%)
Average
A$35.08 (-5.64%)
Lowest
A$27.99 (-24.71%)
News stories
From sources across the web
Profile
Fisher & Paykel Healthcare Corporation Limited is a manufacturer, designer and marketer of products and systems for use in respiratory care, acute care, and the treatment of obstructive sleep apnea. Based in New Zealand, their products and systems are sold in around 120 countries worldwide. FPH is primarily an exporting company, with just 1 percent of revenue coming from New Zealand sales. Wikipedia
About Fisher & Paykel Healthcare Corporatn Ltd
CEOLewis G. Gradon
Employees7.4K
Founded1934
HeadquartersAuckland, Auckland, New Zealand
SectorMedical device
Previous reportsAll values in NZD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in NZD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
544.25M
544.25M
609.95M
609.95M
Cost of goods sold
201.40M
201.40M
217.75M
217.75M
Cost of revenue
201.40M
201.40M
217.75M
217.75M
Research and development expenses
57.05M
57.05M
60.70M
60.70M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
142.75M
142.75M
156.35M
156.35M
Operating expense
199.80M
199.80M
217.05M
217.05M
Total operating expenses
401.20M
401.20M
434.80M
434.80M
Operating income
143.05M
143.05M
175.15M
175.15M
Other non operating income
-
-
-
-
EBT including unusual items
141.90M
141.90M
173.85M
173.85M
EBT excluding unusual items
141.90M
141.90M
173.85M
173.85M
Income tax expense
35.40M
35.40M
46.10M
46.10M
Effective tax rate
24.95%
24.95%
26.52%
26.52%
Other operating expenses
-
-
-
-
Net income
106.50M
106.50M
127.75M
127.75M
Net profit margin
19.57%
19.57%
20.94%
20.94%
Earnings per share
-
-
-
-
Interest and investment income
2.05M
2.05M
2.05M
2.05M
Interest expense
-2.75M
-2.75M
-2.40M
-2.40M
Net interest expenses
-700.00K
-700.00K
-350.00K
-350.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
174.95M
174.95M
204.75M
204.75M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more

Research

AI content may include mistakes. Learn more